J Food Eng
announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July
Now that GLP-1/GIP products have hit the market, several studies have been conducted testing their efficacy
However, our rigorous matching procedures with the intention to achieve a greater level of between-group comparability on a wide range of baseline patient characteristics (i.e., prior GLA exposure history, comorbidities, diabetes severity, and co-medications) and the regression analyses with adjustment for imbalanced baseline characteristics may have minimized this concern
Finer gauge = less discomfort
The functional consequence in animal models is synergistic rather than additive GH output: GHRH-R priming increases the pool of releasable GH vesicles, and GHS-R1a co-stimulation then drives a larger amplitude pulse than either receptor produces alone